Macquarie Flags Softer Trading Conditions in 1Q
By Alice Uribe
Macquarie Group, Australia's biggest investment bank and asset manager, said trading conditions softened in the first quarter of the 2024 fiscal year.
In comments ahead of its annual shareholder meeting on Thursday, Macquarie said the contribution of its operating group to net profit during the three months through June--a measure of earnings before some corporate costs, profit share and income tax--was substantially lower than a year earlier.
"Weaker trading conditions saw Macquarie's Operating Groups deliver 1Q FY 2024 net profit contribution that was substantially down on the first quarter of the 2023 financial year," said Chief Executive Shemara Wikramanayake.
Macquarie said the contribution to net profit of its annuity style businesses was substantially down on a year ago, as was the contribution of its markets-facing businesses.
The company said its financial position comfortably exceeds regulatory minimum requirements, with a group capital surplus of 10.8 billion Australian dollars (US$7.3 billion) at the end of June.
Write to Alice Uribe at alice.uribe@wsj.com
(END) Dow Jones Newswires
July 26, 2023 18:45 ET (22:45 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track